Skip to main content
4SC AG logo

4SC AG — Investor Relations & Filings

Ticker · VSC ISIN · DE000A3E5C40 LEI · 391200QOKN7LGVP0RQ86 F Manufacturing
Open in API
Filings indexed 719 across all filing types
Latest filing 2006-10-10 Regulatory Filings
Country DE Germany
Listing F VSC

About 4SC AG

https://www.4sc.com/

4SC AG is a biopharmaceutical company that formerly focused on the research and development of small-molecule drugs for cancer treatment. The company's strategy centered on addressing diseases with high unmet medical needs by developing innovative therapies that targeted epigenetic mechanisms of action. According to the company's official statements, it currently has no products under development and no operational business.

Recent filings

Filing Released Lang Actions
4SC achieves next milestone in drug discovery collaboration with Sanwa Kagaku Kenkyusho
Regulatory Filings Classification · 98% confidence The document is a press release dated October 10, 2006, announcing the successful completion of a research collaboration between 4SC AG and Sanwa Kagaku Kenkyusho (SKK) regarding drug discovery in the field of diabetes. It details the achievement of milestones, resulting in a payment from SKK, and outlines future responsibilities and participation in royalties. This type of announcement, detailing a specific business development, partnership milestone achievement, or operational update that is not a standard periodic financial report (like 10-K or IR) or a formal regulatory filing (like a proxy or insider trade), fits best under the general category for corporate news or regulatory announcements that don't have a more specific code. Since it is a specific business update rather than a general regulatory filing fallback (RNS), and it is not an earnings release (ER), capital change (CAP), or management change (MANG), the most appropriate classification among the provided options for a specific business/operational update that doesn't fit elsewhere is the general Regulatory Filings (RNS) category, as it functions as a public disclosure of a material event. However, given the content is a specific business development announcement (partnership milestone), and there isn't a 'Business Development' code, RNS serves as the best fit for non-standard disclosures.
2006-10-10 English
4SC erreicht nachsten Meilenstein in Forschungskooperation mit Sanwa Kagaku Kenkyusho
Regulatory Filings Classification · 91% confidence The document is a press release dated October 10, 2006, announcing the successful completion of a research cooperation milestone between 4SC AG and Sanwa Kagaku Kenkyusho regarding diabetes research. It details the achievement, the resulting payment, and future responsibilities. This type of announcement, which is a general corporate update about a specific event (a research milestone payment), does not fit neatly into the specific financial reporting categories (like 10-K, ER, IR) or specific corporate actions (like DIV, SHA, M&A). It is a general news item related to business operations and partnerships. Given the available specific categories, the most appropriate fallback is 'Regulatory Filings' (RNS) as a general corporate announcement that doesn't match the other specialized types.
2006-10-10 German
4SC announces results of the first six months
Earnings Release Classification · 100% confidence The document explicitly states that the company 'published the financial results of the first six months of 2006.' It provides detailed financial figures for the first six months (H1) and the second quarter (Q2) of 2006, including net sales, R&D costs, operating results, and earnings per share. This content structure—a comprehensive financial review for a period shorter than a full year—is characteristic of an Interim/Quarterly Report (IR). It is not a brief announcement (RPA) as it contains substantial financial detail, nor is it the full Annual Report (10-K). H1 2006
2006-08-14 English
4SC gibt Ergebnisse des ersten Halbjahres bekannt
Earnings Release Classification · 100% confidence The document explicitly states: 'Heute veröffentlichte das Biotech-Unternehmen 4SC AG (Frankfurt, Prime Standard: VSC) die Finanzergebnisse des ersten Halbjahres 2006.' (Today, the biotech company 4SC AG published the financial results for the first half of 2006.) It contains detailed financial figures for the first half of the year (Umsatzerlöse, Kosten, Periodenergebnis, Eigenkapitalquote) and also discusses the second quarter results. This content aligns perfectly with the definition of a comprehensive financial report for a period shorter than a year, which corresponds to the Interim / Quarterly Report (IR) category. It is not an Earnings Release (ER) because it is a comprehensive report, not just highlights, and it is not an Annual Report (10-K) as it covers only the first half of the year. H1 2006
2006-08-14 German
Q2 Report 2006
Interim / Quarterly Report
2006-08-14 English
US Patent Granted for 4SC's Clinical Project
Regulatory Filings Classification · 100% confidence The document is a press release dated July 27, 2006, announcing that the US Patent and Trademark Office granted a patent (US patent number 7,071,355) for one of the company's clinical drug candidates (SC12267) and its use in treating diseases like rheumatoid arthritis or cancer. This is a specific announcement regarding intellectual property rights and development progress, not a standard financial report (like 10-K, IR, or ER). It does not fit the definitions for AGM-R, MANG, CT, CAP, DVA, DLST, DIRS, SR, FS, CGR, IRAT, NAV, DIV, PSI, DEF 14A, RPA, SHA, or POS. It is a specific corporate update that is not covered by the other specialized codes. Therefore, the most appropriate general category for a specific, non-financial regulatory/legal update that doesn't fit elsewhere is 'Regulatory Filings' (RNS), as it relates to a legal/IP milestone announcement.
2006-07-27 English

Browse filings by year

21 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.